Gilead Sciences Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 6.15, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Gilead Sciences Inc in Jun 30 2026 quarter, has decreased to 59 days, compared to 60 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 284 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1939 to 2244.

What is Receivable Turnover Ratio?
What is Gilead Sciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GILD Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	5.73 %	8.04 %	11.15 %	11.07 %	2.53 %
Y / Y Revenue Change	10.18 %	4.39 %	4.7 %	2.97 %	1.84 %
Receivable Turnover Ratio (TTM)	6.15	6.09	6.14	6.23	6.35
GILD's Total Ranking	# 2244	# 1939	# 1780	# 1890	# 1815
Accounts Receivable average collection period days	59	60	59	59	57
Seq. Receivable Change	6.62 %	-3.5 %	-3.57 %	6.57 %	8.96 %
Seq. Revenue Change	12.11 %	-12.18 %	2.01 %	9.7 %	6.22 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 27
Healthcare Sector	# 285
Overall Market	# 2244

Receivable Turnover Ratio Statistics
High	Average	Low
7.12	5.87	4.41
(Sep. 30, 2014)		(March 31, 2012)

GILD Company Profile • Back to GILD Efficiency Comparisons • Compare GILD Receivables Turnover Ratio to its Competitors

Financial Statements
Gilead Sciences Inc 's Accounts Receivable	$ 5,055 Millions	Visit GILD's Balance sheet
Gilead Sciences Inc 's Sales TTM	$ 30,457 Millions	Visit GILD's Income Statement
Sources of GILD's Revenues		Visit GILD's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GILD's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GILD's Growth Rates	GILD's Roa	GILD's Inventory Turnover Ratio	GILD's Dividend Comparisons
GILD's Profitability Ratios	GILD's Roi	GILD's Asset Turnover Ratio	GILD's Dividend Growth
GILD's Valuation Ratios	GILD's Roe	GILD's Financial Strength Ratios	GILD's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Lifemd Inc	16.48	$ 163.363 Millions	$ 9.915 Millions
Protagonist Therapeutics inc	15.97	$ 281.992 Millions	$ 17.661 Millions
Neuraxis Inc	15.53	$ 5.316 Millions	$ 0.342 Millions
Agenus Inc	15.44	$ 132.693 Millions	$ 8.595 Millions
Longeveron Inc	15.03	$ 1.187 Millions	$ 0.079 Millions
Medicinova Inc	15.02	$ 0.920 Millions	$ 0.061 Millions
Voyager Therapeutics Inc	14.71	$ 34.459 Millions	$ 2.343 Millions
Halozyme Therapeutics Inc	14.68	$ 1,663.738 Millions	$ 113.332 Millions
Dar Bioscience Inc	14.57	$ 1.345 Millions	$ 0.092 Millions
Nexgel Inc	14.52	$ 11.810 Millions	$ 0.813 Millions
China Pharma Holdings Inc	14.46	$ 3.914 Millions	$ 0.271 Millions
Lftd Partners Inc	14.13	$ 35.335 Millions	$ 2.500 Millions
Talkspace Inc	14.09	$ 246.631 Millions	$ 17.506 Millions
Lifestance Health Group Inc	14.07	$ 1,584.834 Millions	$ 112.665 Millions
Ataibeckley Inc	13.83	$ 4.473 Millions	$ 0.324 Millions
Amneal Pharmaceuticals Inc	13.83	$ 3,117.474 Millions	$ 225.492 Millions
Arvinas Inc	13.49	$ 316.700 Millions	$ 23.475 Millions
Rosecliff Acquisition Corp I	13.43	$ 16.467 Millions	$ 1.226 Millions
Corcept Therapeutics Inc	13.30	$ 830.813 Millions	$ 62.477 Millions
Precipio inc	13.25	$ 27.198 Millions	$ 2.052 Millions
Skinhealth Systems Inc	13.04	$ 289.224 Millions	$ 22.179 Millions
Chemed Corporation	12.94	$ 2,595.001 Millions	$ 200.565 Millions
Qhslab Inc	12.77	$ 3.017 Millions	$ 0.236 Millions
Mannkind Corporation	12.39	$ 393.630 Millions	$ 31.773 Millions
Petvivo Holdings Inc	12.34	$ 1.182 Millions	$ 0.096 Millions
Siga Technologies Inc	12.32	$ 53.659 Millions	$ 4.356 Millions
Alpha Pro Tech Ltd	12.25	$ 62.204 Millions	$ 5.077 Millions
Vivos Therapeutics Inc	12.21	$ 21.135 Millions	$ 1.731 Millions
Milestone Scientific Inc	11.82	$ 8.855 Millions	$ 0.749 Millions
Teladoc Health Inc	11.74	$ 2,489.480 Millions	$ 212.023 Millions

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.